Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
PHASE2
Aim of this phase 2 study is to explore the safety and efficacy of thoracic...
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
PHASE2
This study is a phase II study of AZD6738 in combination with durvalumab in...
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
PHASE2
PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase I...
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
PHASE2
This study will evaluate the efficacy and safety of ceralasertib followed b...
Status
Recruiting
Location
Azienda Ospedaliero Universitaria Maggiore della Carità